Clinical and Economic Considerations for Nivolumab-Based Therapy for Resectable Non–Small Cell Lung Cancer

This clinical brief is sponsored by Bristol Myers Squibb and is intended for payers, formulary committees, or other similar individuals or entities with knowledge and expertise in the area of health care economic analysis carrying out responsibilities for the selection of drugs for coverage, reimbursement, or other population-based health care management.